Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma plc (~292)

  Print      Mail a friend       Annual reports

Monday 09 June, 2008

Antisoma plc

Result of EGM


Antisoma's acquisition of Xanthus Pharmaceuticals Inc. approved by

Antisoma plc (LSE:ASM;  USOTC:ATSMY) announces  that the  resolutions
put to  today's Extraordinary  General  Meeting (EGM)  of  Antisoma's
shareholders were passed with the support of over 89% of votes  cast.
These included a resolution to acquire Xanthus Pharmaceuticals  Inc.,
and, by  association, the  fundraising linked  with the  acquisition.
Full details of the proxy voting are available on Antisoma's  website

Copies of the resolutions passed at the EGM today are available for
inspection at the UK Listing Authority's Document Viewing Facility,
which is situated at:

The Financial Services Authority
25 The North Colonnade
Canary Wharf
London E14 5HS
Tel: +44 (0) 20 7066 1000

A further announcement will be made regarding admission of the shares
issued in connection with the acquisition and fundraising and the
completion of the transaction.


Antisoma plc                                     Tel: +44 (0)7909 915
Glyn Edwards, Chief Executive Officer
Daniel Elger, Director of Communications

Buchanan Communications                          Tel: +44 (0)20  7466
Mark    Court/Lisa     Baderoon/Rebecca     Skye

Piper Jaffray Ltd                                Tel: +44 (0)20  3142
Neil Mackison
Rupert Winckler

Background to the acquisition and fundraising
On 16 May, Antisoma announced that  it had entered into an  agreement
to acquire private US oncology company Xanthus Pharmaceuticals,  Inc.
in an all-share deal valued at  GBP 26.8 million  (USD 52.2  million)
and that  it had  simultaneously  executed a  fundraising  providing,
before expenses,  an  additional GBP  20.9  million to  the  Enlarged
Group. Further details are available in the press release of 16 May.

Notes and disclaimers
Piper Jaffray, which  is authorised and  regulated in the  UK by  the
Financial Services  Authority, is  acting  as financial  adviser  and
broker to Antisoma in connection  with the proposals and no-one  else
and will  not  be  responsible  to anyone  other  than  Antisoma  for
providing the protections  afforded to clients  of Piper Jaffray  nor
for providing  advice in  relation  to the  proposals nor  any  other
matter referred to in this announcement.

Words and expressions used in this announcement will have the same
meaning as defined in the prospectus and circular that has been sent
to shareholders.

This document does not constitute an offer or invitation to purchase
or subscribe for any securities of Antisoma and no part of it shall
form the basis of or be relied upon in connection with any contract
or commitment whatsoever.

The information contained herein is not for publication, distribution
or release in or into the United States.  The material set forth
herein is for informational purposes only and is not intended, and
should not be construed, as an offer of securities for sale in the
United States.  The securities described herein have not been and
will not be registered under the U.S. Securities Act of 1933, as
amended (the "Securities Act"), or the laws of any state or other
jurisdiction, and may not be offered or sold within the United
States, except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act and
applicable laws of any state or other jurisdiction.  There is no
intention to register any portion of the securities described herein
in the United States.

This document is not an offer to sell or the solicitation of an offer
to buy any securities in any jurisdiction where such offer or sale is
not permitted.

Certain matters discussed in this statement are forward looking
statements that are subject to a number of risks and uncertainties
that could cause actual results to differ materially from results,
performance or achievements expressed or implied by such statements.
These risks and uncertainties may be associated with product
discovery and development or licensing activities, including
statements regarding the clinical development programmes, the
expected timing of clinical trials and regulatory filings,
out-licensing opportunities, and funding requirements. Such
statements are based on management's current expectations, but actual
results may differ materially.



a d v e r t i s e m e n t